TEST DIRECTORY

0 selected

Laboratory：Akiruno

○Thyroid Cancer Oncomine DxTT Multi-2 Gene CDx(46)FF

CODE：00W56 7

  • TEST NAME SPECIMEN
    REQUIREMENT
    （ｍL）     CONTAINER CAP COLOR STORE
    TEMPERATURE
    (STABILITY)     TURNAROUND
    TIME (DAY)     METHODOLOGY REFERENCE RANGE
    (UNIT)
  • Specified days
    Thyroid Cancer Oncomine DxTT Multi-2 Gene CDx(46)FF
    tissue
    100mg
    ARR Freeze
     6-11 Next Generation Sequencing (NGS)

    A method that uses a next-generation sequencer to simultaneously determine the base sequences of a huge number of DNA fragments.

COMMENT


The purpose of this study is to analyze RET gene mutation, RET fusion gene and BRAF gene V600E mutation in genomic DNA and RNA extracted from cancer tissue to assist determination of the indication of the drugs listed in the attached table for thyroid carcinoma and medullary thyroid carcinoma. In addition, for research purposes only, we will also report on the analytical results of 46 genes that have not yet received pharmaceutical approval.
Acceptable days are Monday to Friday.
Please make sure that the material contains the tumor site before submitting it. Please avoid duplicate requests with other items. Since this test method is more susceptible to contamination, please handle the specimens with care when collecting them.
When requesting this test, please be sure to request the nucleic acid extraction item (item code No.0M961 2) at the same time.
●Notes
After collecting the specimen, please process it immediately. Please note that if the number of cells in the submitted specimen is low, the test may not be possible.

CONTAINER

supplementary information

Notifications of URL changes/lab information added

ラボを選択してください

Choose a laboratory

Notifications of URL changes/lab information added

Laboratory List

Advanced search